...
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Supplementation of folic acid and vitamin B12 reduces plasma levels of asymmetric dimethylarginine in patients with acute ischemic stroke
【24h】

Supplementation of folic acid and vitamin B12 reduces plasma levels of asymmetric dimethylarginine in patients with acute ischemic stroke

机译:叶酸和维生素B12的补充降低急性缺血性中风患者的血浆不对称二甲基精氨酸水平

获取原文
获取原文并翻译 | 示例
           

摘要

Increased levels of asymmetric dimethylarginine (ADMA) have been observed in patients with acute ischemic stroke. We aimed to investigate the correlation between ADMA and ischemic stroke, and evaluate the effect of supplementation of folic acid and vitamin B12 on concentrations of ADMA. Patients were randomized into intervention and non-intervention groups within 3 days after symptom onset. Intervention group patients were treated with folic acid (5 mg daily) and vitamin B12 (500 μg twice daily) for 12 weeks. ADMA and homocysteine (Hcy) concentrations were measured before treatment (baseline) and 2 and 12 weeks after treatment. The laboratory measures were also collected from healthy controls. Eighty five subjects were enrolled in this study, from whom 72 with complete baseline and follow-up laboratory data were included in the present analysis. Thirty four patients were assigned to the intervention group and 38 patients to the non-intervention group. Sixty people were enrolled as healthy controls. Levels of ADMA and Hcy were raised (p 0.05) in patients with acute ischemic stroke. With supplementation of both folic acid and vitamin B12, the levels of ADMA and Hcy decreased significantly at 2 and 12 weeks (p 0.05). The present study reconfirmed that ADMA can be regarded as a risk biomarker for acute ischemic stroke. We observed that with supplementation of folic acid and vitamin B12, levels of ADMA were decreased in patients with acute ischemic stroke.
机译:在急性缺血性中风患者中观察到不对称二甲基精氨酸(ADMA)水平升高。我们旨在研究ADMA与缺血性中风之间的相关性,并评估补充叶酸和维生素B12对ADMA浓度的影响。症状发作后3天内将患者随机分为干预组和非干预组。干预组患者接受叶酸(每天5 mg)和维生素B12(每天500μg每天两次)治疗12周。在治疗前(基线)以及治疗后2周和12周测量ADMA和高半胱氨酸(Hcy)浓度。实验室措施还从健康对照中收集。这项研究招募了85位受试者,其中72位具有完整的基线和随访实验室数据被包括在本分析中。干预组有34例患者,非干预组有38例患者。共有60人作为健康对照。急性缺血性卒中患者的ADMA和Hcy水平升高(p <0.05)。补充叶酸和维生素B12后,ADMA和Hcy的水平在第2周和第12周显着降低(p <0.05)。本研究证实,ADMA可被视为急性缺血性卒中的危险生物标志物。我们观察到,补充叶酸和维生素B12后,急性缺血性卒中患者的ADMA水平降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号